Corcept Therapeutics
CORT
CORT
348 hedge funds and large institutions have $3.19B invested in Corcept Therapeutics in 2026 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 110 increasing their positions, 127 reducing their positions, and 102 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
less funds holding
Funds holding: →
13% less repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 127
31% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 102
50% less call options, than puts
Call options by funds: $49.6M | Put options by funds: $99.1M
Holders
348
Holding in Top 10
7
Calls
$49.6M
Puts
$99.1M
Top Buyers
| 1 | +$55.3M | |
| 2 | +$50.2M | |
| 3 | +$37.8M | |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$36.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$35.5M |
Top Sellers
| 1 | -$34.6M | |
| 2 | -$28.4M | |
| 3 | -$23.7M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$22.8M |
| 5 |
Morgan Stanley
New York
|
-$21.4M |
